Meds Apotek

Summary for the period January – March 2025:

• Net sales totalled SEK 241.9 (187.0) million, an increase of 29.4%.
• Gross profit margin of 28.9% (28.5%).
• EBIT totalled SEK 5.5 million (-5.3) and EBIT % of 2.3 percent (-2.9)
• Profit for the period totalled SEK 5.4 million (-6.3)
• Operating cash flow totalled SEK 16.7 million (8.3)

”Despite global geopolitical uncertainty and economic challenges, MEDS continues to deliver in line with our long-term growth and profitability strategy. We have seen linear improvement in profitability for 13 consecutive quarters and are EBIT positive over the last 12 months. The results clearly demonstrate the strength of the organisation we have built and the scalability of our business model. The record-high profitability achieved during the quarter is confirmation of our strategy. Strong and consistent investments in our brand, IT and logistics over the past seven years are now yielding results. At the same time, we are continuing to strengthen our operational efficiency, which is reflected in strong cash flow during the quarter.”, says Björn Thorngren, CEO at MEDS.

MEDS has not published an interim financial report for the period. All key figures are based on the company's consolidated accounts, which have been prepared in accordance with IFRS.